Novaccess Global Inc XSNX

Healthcare Biotechnology

NovAccess Global Inc. is a biopharmaceutical company, which develops immunotherapies to treat brain tumor patients in the United States. The Company specializes in research related to utilizing a patient’s own immune system to attack the cancer. Its dendritic cell-based immunotherapy utilizes a combination of Toll-like receptor adjuvants for an enhanced antitumor response. The therapy is designed to utilize the patient’s tumor antigens and immune cells, dendritic cells, in combination with TLR adjuvants to initiate an efficient antitumor immune response. This process includes obtaining the patients' tumor cells after surgery, and precursors cells that are matured into dendritic cells from peripheral blood. Its TLR-AD1 platform technology is a vaccine immunotherapy for the treatment of aggressive brain cancers, including glioblastoma and other high-grade gliomas. TLR-AD1 technology has a scope of use and is embodied in various different product lines for different clinical situations.

OTCQB:XSNX - Post by User

Novaccess Global Inc > .1.7M @ .002c... Back down SOLAR in high demand !!!

<< Previous

Bullboard Posts

Next >>

Post by mramon Jun 19, 2018 2:39pm

181 Views

Post# 28193412

.1.7M @ .002c... Back down SOLAR in high demand !!!

Recent Trades - Last 10 of 41

Time ET	Ex	Price	Change	Volume
14:14:05	Q	0.002	-0.0005	1,727,898
14:11:34	Q	0.0021	-0.0004	72,102
14:07:30	Q	0.0021	-0.0004	100,000
14:06:03	Q	0.0021	-0.0004	25,000
14:06:03	Q	0.0021	-0.0004	147,102
14:06:03	Q	0.0021	-0.0004	727,898
14:01:44	Q	0.0021	-0.0004	100,000
13:44:17	Q	0.0023	-0.0002	58,500
13:35:04	Q	0.0022	-0.0003	381,500
13:34:28	Q	0.0022	-0.0003	27,000